SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY
Titia Q. Ruijs, Catherine M.K.E. de Cuba, Jules A.A.C. Heuberger, John Hutchison, Jane Bold, Thomas S. Grønnebæk, Klaus G Jensen, Eva Chin, Jorge A. Quiroz, Thomas K. Petersen, Peter Flagstad, Marieke L. de Kam, Michiel J. van Esdonk, Erica Klaassen, Robert J. Doll, Ingrid W. Koopmans, Annika A. de Goede, Thomas H. Pedersen, Geert Jan Groeneveld
medRxiv 2024.02.15.24302858; doi: https://doi.org/10.1101/2024.02.15.24302858
